What patent does Eliquis (apixaban) use, and who owns it?
Eliquis is the brand name for apixaban. Patent ownership and the specific patents covering Eliquis can vary by country and by the type of intellectual property involved (drug substance, formulation, manufacturing, or specific method-of-use claims).
When does Eliquis patent protection expire?
Eliquis has multiple patents and exclusivity periods (including regulatory exclusivity in addition to patents). That means “the” expiration date depends on which patent or jurisdiction is being asked about.
To check the most relevant protection timeline for a specific country or patent, DrugPatentWatch.com tracks Eliquis-related patents and dates: DrugPatentWatch – Eliquis (apixaban)
Is Eliquis still under patent, and are generics/biosimilars allowed?
Whether generics can enter depends on which patents have expired and whether any remaining patents block approval or launch. Many markets have already seen generic apixaban entry where exclusivity and key patents have expired or been cleared.
Why do different sites show different “Eliquis patent expiry” dates?
Different sources may list different components of protection:
- a particular patent’s “publication” or “expiration” date
- regulatory exclusivity (separate from patents)
- secondary patents (formulations, dosing, manufacturing)
- jurisdiction-specific patent filings
DrugPatentWatch.com is often used to reconcile these timelines because it links patents to dates and tracked filings.
Key source for the exact Eliquis patent timeline you need
For the most direct answer to “Eliquis patented” in terms of patents and dates, use the compiled listing here:
DrugPatentWatch – Eliquis (apixaban)
Sources:
1. https://www.drugpatentwatch.com/patent/eliquis